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Introduction
Streptococcus pneumoniae is one of the leading bacterial 
cause of community-acquired pneumonia, acute otitis me-
dia (AOM), bloodstream infection (bacteraemia), sinusitis 
and meningitis, particularly affecting young children and 
elderly people. In particular, pneumococcal pneumonia 
represents one of the major causes of childhood mortality 
in developing countries and of adult mortality worldwide, 
accounting for 30-50% of pneumonia cases [1].
The best preventive strategy is vaccination, that is made 
complicated by T-indipendent nature of polysaccharide 
antigen, and by high heterogeneity of pneumococcus. In 
fact, more than 90 immunologically different serotypes 
of pneumococci have been described but less than 30 
types account for the majority (> 90%) of invasive dis-
ease [2]. Individual serotypes may vary in their distri-
bution over time and geography [3] and differ in their 
prevalence, age distribution and degree of antimicrobial 
resistance [4]. To overcome the inability of bacterial 
polysaccharides to induce T-cell response, a second-
generation conjugate vaccines were designed, developed 
and extensively evaluated during the 1990s.
The introduction in the USA in 2000 of the 7-valent con-
jugated vaccine (PCV7), and the rapid implementation 
of the coverage in children has determined a dramatic 
decrease of incidence of invasive (IPD) and non-inva-
sive pneumococcal disease (non-IPD), not only among 
vaccinated children but even among unvaccinated chil-
dren and adults as a result of a striking herd immunity 
effect [5]. Selective pressure applied by vaccination has 
lead to an increased role of non-vaccine serotypes (se-
rotype replacement) and may favour the emergence of 
successful strains, originally of vaccine serotype, that 
have acquired a non vaccine serotype through capsular 
switching [6]. In particular, the emergence of non-vac-
cine serotypes such as 19A, 15, 1, 7F, involved in IPD 
and non-IPD, has been reported elsewhere [7, 8].
The earlier introduction in late 2008 to early 2009 of 
PCV10 (PCV7 plus serotypes 1, 5, 7F) and then of 
PCV13 vaccine, added with serotypes 3, 6A and 19A, 
has offered a significant benefit, with a reached cover-
age of 59% of IPD in children younger than 5 years, 
whereas PCV7 covered 36% of cases [9].
Serotypes included in both the 10- and 13-valent PCVs 
accounted in fact for 10 million cases and 600,000 deaths 
worldwide [10].
The ability of PCV7, PCV10 and PCV13 to maintain re-
duction of IPD and non-IPD rates has been questioned. 
Nowadays, the global effect of conjugate vaccines is not 
the reduction of the overall prevalence of nasopharyngeal 
colonization in the target population, i.e. children in the first 
years of life, but, by reducing vaccine serotypes, better suit-
ed to causing invasive disease, a decrease of IPD. There-
fore, several factors are both critical and informative to un-
derstand the changing population biology of this pathogen 
and the future effectiveness of conjugate vaccine [11].
A central role is played by pathogenecity and virulence 
determinants of S. pneumoniae and by their distribution 
among vaccine and non-vaccine serotypes.
Although host and bacterial factors both seem to contribute 
to IPD pathogenicity [12], pneumococcal virulence fac-
tors, above all the capsular polysaccharide, are thought to 
play an important role on pneumococcal disease outcome 
and have been considered as potential vaccine candidates. 
Nevertheless, one study have suggested that even clonal 
types and properties may influence invasive capacity and 
render pneumococcal strains more efficient pathogens, 
pointing out the importance of the genotype [13].
Purpose of this review is to deepen the recent data emerged 
on determinants able to influence invasive ability of pneu-
mococcus and its propensity to determine non-IPD, and to 
correlate invasiveness with bacteria serotype.
Pneumococcal virulence factors
In the recent years a great number of pneumococcal viru-
lence factors have been described, but only certain pro-
teins are probably the best candidates for use as vaccine 
antigens [14, 15]. Hereinafter the individual contributions 
of each known virulence factors to the pathogenesis of 
S. pneumoniae infections and their impact are reported.
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Capsule
The pneumococcal capsular polysaccharide represents 
an indispensable virulence factor due to its strongly anti-
phagocytic activity, in fact spontaneous non-encapsulat-
ed strains are almost completely avirulent [14].
The capsule is covalently linked to the surface of the 
cell-wall peptidoglycan, which itself represents a viru-
lence determinant, and protects S.pneumoniae against 
phagocytic clearance by blocking the deposition and 
function of opsonins such as C3b factor and the interac-
tion with the Fc region of IgG.
Interestingly, the presence of a heavy capsule could 
contribute to disease severity. More heavily encapsu-
lated serotypes tend to be more prevalent among pae-
diatric carriage isolates even if they appear to be less 
invasive [16]. Nevertheless, they are more frequently 
associated to severe disease when they do invade. It 
has been demonstrated that pneumococcal isolates can 
be distinguished by their opaque or transparent colony 
morphology and that the organisms spontaneously alter-
nate between the two phases. During the initial stages of 
colonization, transparent variants with a thinner capsule 
predominate since their greater capacity for adherence. 
However, the presence of a thick capsule could promote 
the persistence of pneumococcal strains in the nasophar-
iynx, lungs and blood by protecting bacteria against host 
immune response [15, 17] such as neutrophil-mediated 
killing [18].
Capsular composition in different serotypes may influ-
ence their invasive capacity as a reflection of their abil-
ity to resist phagocytosis together with their different 
ability to trigger inflammatory responses [19].
Finally, the presence of a heavy capsule could contribute 
to antibiotic resistance [20].
Pilus
Pilus-like structures have been identified beyond the 
polysaccharide capsule in S. pneumoniae and a pos-
sible role in enhancing adhesion to host cells was sup-
posed.
These adhesive pili-like appendages are encoded by the 
pneumococcal rlrA islet, present in some, but not all, 
clinical isolates. Introduction of the rlrA islet into an 
encapsulated rlrA-negative isolate allowed pilus expres-
sion, enhanced adherence to lung epithelial cells, and 
provided a competitive advantage upon mixed intranasal 
challenge of mice [21].
Basset et al. [22] have suggested that the pilus does not 
appear to be associated with increased virulence in hu-
mans, despite the data obtained from a mouse study [21] 
and that the presence of pilus may be associated only 
with certain serotypes, especially vaccine serotypes. 
Therefore, the reduction observed in invasive disease 
caused by vaccine serotypes after the introduction of 
conjugate vaccines have also meant a reduction in pili-
ated strains.
Cell-wall components
Pneumococcal cell-wall is composed by several mol-
ecules involved in the adhesion to the host and able to 
induce strong inflammatory responces.
In particular, phosphorylcoline linked to teichoic and 
lipoteichoic acids acts as an adhesion, binding platelet-
activating factor receptor (rPAF) on host tissues and 
promoting airway colonization.
Associated to the cell-wall have been described three major 
complexes of cell surface proteins: choline-binding pro-
teins (PspA, PspC or CbpA, LytA) covalently anchored to 
phosphorylcoline, lipoprotein and proteins covalently asso-
ciated to the cell-surface anchorage domain LPXTG [15].
Choline-binding proteins
CBPs are cell-surface proteins characterized by a specific 
choline binding motif consisting of several repeat sequenc-
es of approximately 20 amino acids which appears to bind 
to the pneumococcal cell surface through phosphorylco-
line associated to teichoic and lipoteichoic acids [23].
PspA, known as the protective antigen, is an 84-kDa pro-
tein that inhibits complement mediated opsonization, prob-
ably through its electronegative properties [15]. Moreover, 
the capacity of PspA to prevent the fixation of complement 
seemed to be correlated to the capsular type [24].
CbpA is considered the most important pneumococcal 
adhesin, essential for pneumococcal carriage. CbpA is 
also characterized by its ability to bind C3 and secretory 
IgA thereby favouring translocation of pneumococcus 
across the respiratory epithelium [25].
LytA, a N-acetylmuramoyl-L-alanine amidase, repre-
sents the major enzyme responsible for cellular autolysis 
and plays a role in cell-wall growth and turnover [26].
Lipoproteins
More than 40 pneumococcal cell surface lipoproteins 
have been described [27]. Pneumococcal surface anti-
gen A (PsaA), Pneumococcal iron acquisition A (PiaA) 
and pneumococcal iron uptake A (PiuA) are reported 
to be essential for pneumococcal virulence [17]. PsaA 
plays an important role in pneumococcal adherence as is 
a component of an ATP-binding cassette transport sys-
tem, essential for manganese uptake.
The importance of PiaA and PiuA resides in their im-
munogenicity and, consequently, in their possible use in 
pneumococcal vaccine development [28].
LPXTG-anchored proteins
LPXTG is an amino acids sequence motif which is rec-
ognized by a specific transpeptidase enzyme responsible 
for the attachment of several surface-located proteins. 
StrA, a sortase transpeptidase, has been reported to have 
a role in pneumococcal adhesion and invasion [29].
Esoenzymes
Beyond cell-wall related virulence factors, other im-
portant determinants of S. pneumoniae are involved in 
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bacterial pathogenicity, in particular pneumolysin and 
neuraminidase enzymes.
Pneumolysin
This enzyme is a powerful cytoplasmic toxin of 52kDa, be-
longing to the family of thiol-activated cytolysins, that oli-
gomerizes in the membrane of the target cell to form a large 
transmembrane pore. Pneumolysin is released by autolysis 
of the cell and binds to cholesterol present on the host cell 
surfaces. This enzyme shows its cytolitic activity on cili-
ated bronchial epithelial cells, alveolar epithelial cells and 
pulmonary endothelium. This activity includes inhibition of 
ciliary beating and of respiratory burst, separation of tight 
junctions of alveolar epithelial cells, induction of cytokine 
synthesis and CD4+ T-cell activation and chemotaxis [30]. 
Further, pneumolysin is essential for bacterial spread to the 
bloodstream and is involved in brain damaging through di-
rect neurotoxicity [31].
Interestingly, strains producing a non-cytolitic pneumo-
lysin was shown to be more virulent and it was suggest-
ed that this non-haemolytic pneumolysin could activate 
TLR4-dependent responces and stimulate the production 
of interferon-γ [32].
Neuraminidase
This sialidasis cleave sialic acid residues from a wide 
range of soluble proteins, such as lactoferrin, IgA2 and 
other secretory components facilitating colonization and 
invasion by increasing the number of adhesins available 
for pneumococcal binding [33]. There are three pneu-
mococcal enzymes with neuraminidase activity: NanA, 
NanB, NanC. It has been suggested that NanA and NanB 
promote pneumococcal survival in the respiratory tract 
and bloodstream [34], whereas NanC is frequently found 
in isolates from cerebrospinal fluid and tissue-specific 
role has been proposed [35].
Hyaluronidase
The importance of this enzyme is connected to its de-
grading activity of connective tissue and its involvement 
in the pathogenesis of human pneumococcal meningi-
tis. Strains with higher hyaluronidase activity have been 
demonstrated to cross the blood-brain barrier and dis-
seminate more effectively [36].
Ability of S. pneumoniae serotypes  
to cause invasive disease
Invasive pneumococcal disease represents one of the 
leading causes of morbidity and mortality worldwide, 
with a 5-35% of mortality depending on site of infection, 
age and comorbidity [37].
Changes in serotype distribution of IPD are inextricably con-
nected to the serotype distribution of pneumococcal coloni-
zation among children, the main reservoir of the pathogen.
Many studies have described the serotypes of isolates 
involved in invasive disease and in carriage [38,39] but 
only few have investigated, in the same community and 
in the same time period, the relationship between the 
isolates involved in invasive disease and those carried 
by the same population.
Brueggemann et al. [40] have suggested and demon-
strated the importance of the capsular serotype in de-
fining pneumococcal invasiveness, quantified and com-
pared the disease potential of individual serotypes or 
clones thus demonstrating their different ability to cause 
invasive disease (Fig. 1). Moreover, the study, conduct-
ed among children < 5 years in Oxford, confirmed that 
invasive strains own significantly less genetic diversity 
than the carriage isolates and that in both the populations 
a strong association between serotype and ST exists. 
Noteworthy, serotypes most commonly found among in-
vasive disease in children were the ones included in the 
7-valent conjugate vaccine, but they differed in their dis-
ease potential. In particular, vaccine serotypes 4, 14 and 
18C were significantly associated with invasive disease. 
Of particular concern resulted non vaccine serotypes 1, 
7F and 19A (Tab. I).
In another study, a meta-analysis was conducted on 7 
data sets of invasive and carriage pneumococcal isolates 
from young children coming from the same region during 
roughly the same time period. Odds ratios of pneumococ-
cal serogroups were calculated for each study and it was 
demonstrated that serogroup invasive disease potential did 
not differ temporally or geographically [41]. Finally, the 
meta-analysis results showed an inverse correlation be-
tween invasive disease and carriage prevalence: serotypes 
with the highest odds ratios were the least commonly cir-
culating whereas serotypes more commonly carried were 
the least invasive. This could be partly explained by differ-
ences in serotype and serogroup-specific carriage duration 
but serotype or serogroup remains one of the most impor-
tant determinants of invasiveness.
Although some limitations, these 2 studies provide im-
portant information and instruments for the evaluation 
of the disease incidence of the different serotypes circu-
lating in a community, which largely depends on their 
disease potential and could be altered after vaccination.
A similar study was conducted in Finland [42] and the 
odds ratios for invasive disease of different serotypes 
and clones were obtained. Data found in Oxford resulted 
to be comparable with finnish results, indeed, all se-
rotypes with an ORs > 1 in the Oxford study also had 
ORs > 1 in Finland, with the exception of serotype 1 
(Tab. I, Fig. 1).
Furthermore, both host and bacterial factors seem to 
contribute to IPD pathogenicity. A nationwide popula-
tion-based study conducted in Denmark, demonstrated 
the association between specific invasive pneumococcal 
serotypes and mortality related to IPD and also showed 
the influence of several risk factors, such as: age, ethnic-
ity, meningitis, comorbid conditions etc, in mortality af-
ter IPD [38] (Tab. I). Serotype 1 represented 15% of all 
IPD cases in the study population, followed by serotypes 
14, 4, 7F, 9V, 3, 8, 12F, 23F and 6B. Serotypes 14, 6B, 
18C, 7F, 19F, 1, 6A, 23F, 4 and 9V accounted for 80% 
of IPD cases in children < 5 years of age, with serotypes 
6B, 14, 7F, 18C, 19F, 6A and 23F involved in 70% of 
meningitis cases. In patients older than 5 the most fre-
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Fig. 1. odds ratio association (95%ci) of pneumococcal sertypes with invasive disease [40, 48, 42].
Serotype 18C
Serotype 14
Serotype  4
Serotype  1
Serotype 7F
Serotype 19A
Serotype  3
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Serotype 6B
Serotype 33F
Serotype 22F
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quent serotypes resulted to be 1, 4, 14, 7F, 3, 9V, 12F, 8 
and 23F, accounting for 67% of all cases. Furthermore, 
danish results, according to previous studies [38] dem-
onstrated that highly invasive serotypes, e.g. serotypes 
1, 7F and 14, were not related to high mortality rates 
and resulted more invasive in children with low rates of 
comorbid conditions (Tab. I). No statistically significant 
serotype-mortality association could be demonstrated 
for children because of low childhood mortality (< 3%), 
whereas in developing countries mortality ranges from 
10%-40%, probably due to poorer access to health care, 
higher prevalence of comorbid conditions, malnutrition 
and HIV. Serotypes 3 and 19A were associated with 
high- mortality in older children and adults, together 
with serotypes 31, 11A, 35F, 17F, 16F, 19F, 15B and 
10A as compared with serotype 1. In addition, comor-
bidity resulted to influence IPD related-mortality rate, 
supporting data of a Swedish study which suggested that 
comorbidity may influence the invasiveness of specific 
serotypes in susceptible populations, indicating that se-
rotypes with low invasive disease potential may behave 
as opportunistic pathogens in patients with unapparent 
comorbidity [43].
Several other studies already suggested relationships 
between serotype and outcome of disease [44,45] and 
demonstrated that host related factors are relevant as 
well [46]. In contrast, some other authors suggested that 
there is no association between serotype and outcome of 
disease, and that host factors are better predictors of IPD 
and associated morbidity and mortality than are micro-
bial factors [47]. However, in this work information on 
serotype appeared to be dichotomized thus altering the 
real risk associated to specific serotypes.
Recently Yildirim et al. [48] suggested that the most in-
vasive serotypes were 18C, 33F, 7F, 19A, 3 and 22F both 
among vaccine and non-vaccine serotypes (Tab. I, Fig. 1).
Association of S. pneumoniae serotype 
and pneumococcal pneumonia
S. pneumoniae is the most common cause of communi-
ty-acquired pneumonia (CAP) in children and the eld-
erly [49].
Pneumonia is considered one of the major causes of 
childhood mortality in developing countries, and of 
adult mortality worldwide [50].
In Europe and the United States, pneumococcal pneumo-
nia is the most common community-acquired bacterial 
pneumonia, estimated to affect approximately 100 per 
100 000 adults each year [51]. For adults with pneumo-
coccal pneumonia the mortality rate averages 10-20%.
No more less is known about the strains and serotypes 
from pneumonia, although several studies have suggest-
ed a relationship between some serotypes and certain 
disease presentations. In particular, a high proportion of 
severe pneumonia cases were reported for serotypes 1 
and 3 [52-53] (Tab. I).
A report on the association of nasopharyngeal S. pneu-
moniae serotypes with CAP suggested that carriage of 
serotypes 1 and 5 may be highly associated with radiog-
raphycally and clinically more severe childhood pneu-
monias [54] (Tab. I).
A recent meta-analysis of serotype-specific outcomes for 
adults and paediatric patients with pneumococcal pneumo-
nia and meningitis reported that clinical outcome in bac-
Tab. I. recent studies noting associations between serotypes and clinical manifestations among different age groups.
Reference and Location Study period Age group Number of 
isolates
Serotypes
invasive pneumococcal diseases
martens p, et al., holland [37] 1990-2001 > 16 years old 464 1, 3
Brueggemann aB, et al., uK [40] 1995-2001 > 5 years old 150 4, 14, 18c, 1, 7f, 19a
hanage Wp, et al., finland [42] 1995-1999 < 2 years old 224 14, 18c, 19a, 6B
harboe ZB, et al., denmark [38] 1977-2007 all age gropus 18858 1, 14, 4, 7f, 9v, 3, 8, 12f, 
23f, 6B
ruckinger s, et al., germany [46] 1997-2003 > 16 years old 494 7f
yildirim i, et al., usa [48] 2003/2004,2006/2007
2008/2009
≤ 7 years old 206 18c, 33f, 7f, 19a, 3, 22f
pneumonia
camou, et al., uruguay [53] 1994-2001 > 5 years old 506 1, 3
dagan r, et al., israel [54] 2001-2004 > 5 years old 435 1, 5
yu J, et al., usa [57] 2007-2009 pediatric 
patients
49 1, 3, 7f/a, 19a
resti m, et al., italy [56] 2007-2009 0-16 years old 753 1
acute otitis media
hanage Wp, et al., finland [64] 1994-1997 < 2 years old 149 19f, 23f
Kilpi t, et al., finland [58] 1994-1997 < 2 years old 329 19f, 23f, 6a, 6B, 14
shouval ds, et al., israel [65] 200-2004 < 3 years old 3200 1, 3, 5, 12f, 19a, 19f
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teriemic pneumonia, such as carriage prevalence and inva-
siveness, seemed to be a stable serotype-associated proper-
ty. In particular, an increased risk of death was associated 
with serotypes 3, 6A, 6B, 9N and 19F among pneumonia 
patients, and a higher risk was observed for serotypes 19A 
and 23F, although not statistically significant [55].
Several studies have reported the distribution of specific 
serotypes as cause of IPD by age groups. In particular, 
serotype 1 was classified as leading cause of bacteriemic 
pneumonia and paediatric parapneumonic empyema, in 
children older than 2 years [56].
A recent study conducted in USA reported a strong associa-
tion between serotypes 1, 3, 7F/A and 19A and pneumonia 
with pleural effusion in paediatric patients [57] (Tab. I).
An observational study conducted from April 2007 to 
June 2009 on children aged 0-16 years admitted to 83 
paediatric hospital in Italy with a diagnosis of communi-
ty-acquired pneumonia, reported that serotype 1 was the 
most frequently found and was significantly associated 
with complicated cases and older age according to previ-
ous finding [56] (Tab. I).
Highly invasive disease potential serotypes such as 1, 5 
and 7F were correlated to complicated parapneumonic 
effusion or empyema in younger adults [1].
Association of S. pneumoniae serotype 
and acute otitis media
S. pneumoniae is the most frequent pathogen isolated 
from middle ear fluid (MEF) in patients with Acute Oti-
tis Media (AOM), being detected in 26-48% of cases by 
bacterial culture methods [58, 59].
The nasopharyngeal carriage of S. pneumoniae is impor-
tant in the pathogenesis of AOM. The carriage rate of 
S. pneumoniae varies from 9% to 52% between popula-
tions in healthy children, but increases during a respira-
tory infection without AOM and is at its highest, 45% to 
91%, during AOM episodes. During pneumococcal AOM 
the nasopharyngeal carriage rate of S. pneumoniae reaches 
97 to 100% [60]. The occurrence of AOM is affected by 
both host factors and environmental factors. Predisposing 
host factors include young age, male gender, racial factors, 
allergic rhinitis, immune deficiency, cleft palate, cranio-
facial abnormalities and genetic predisposition [61]. Fur-
ther, factors that increase nasopharyngeal colonization in 
children include young age, day-care attendance, parental 
smoking, the winter season and antibiotics [62].
Several studies have suggested a relationship between 
specific serotypes of S. pneumoniae and their ability to 
cause invasive disease [63], though, for mucosal infec-
tions like AOM it seems that there is much less variation 
in the ability of different pneumococcal serotypes and 
clones to cause AOM, thus suggesting that all serotypes 
are equally able to cause AOM [64].
Moreover, association of the common childhood sero-
types 6B, 9V, 14 and 19F with AOM, not necessarily 
implies a propensity of these serotypes to cause AOM, 
as they are the most commonly carried in the nasophar-
ynx of children [65, 66].
In a recent Finnish study the most frequent serotypes 
in MEF isolates from children with AOM were 19F, 
23F, 6A, 6B and 14, which accounted for 73% of all 
cases [42] (Tab. I).
Hanage et al. [64] investigated the abilities of pneumo-
coccal serotypes and clones to cause AOM, by com-
paring the distribution of pneumococcal serotypes and 
clones causing AOM in children < 2 years of age with 
those carried in the nasopharynx of children of the same 
age, in the same region and time period (Tab. I).
No significant association with AOM of individual se-
rotypes was demonstrated, suggesting little variation in 
their ability to cause disease, with the exception of se-
rotypes 19F and 23F, and no significant difference in 
distribution of AOM and NP isolates was observed. Fur-
thermore, genotype appeared to be an important marker 
of the ability of a strain to cause AOM, thus suggesting 
that serotype may play a lesser role than that commonly 
associated to IPD. Consequently, serotype replacement 
potentially may reduce the long-term efficacy of the 
conjugate vaccines against AOM because it would lead 
to AOM caused by non vaccine serotypes instead of vac-
cine serotypes, without reducing the overall incidence 
of disease.
Another study demonstrated that specific serotypes 
causing IPD, AOM or AC possess different disease po-
tential in relation with the site of infection. In particu-
lar, serotypes 1, 3, 5, 12F, 19A and 19F were associated 
with AOM, providing important information regarding 
specific disease potential of non-vaccine serotypes [65] 
(Tab. I).
Discussion
Pneumococcal serotypes and clones widely differ in their 
ability to cause disease, as a result not only of their dif-
ferences at the capsular locus and genetic background, 
but also of bacteria-host interactions which play a sig-
nificant role in determining IPD.
The introduction of the heptavalent pneumococcal con-
jugate vaccine formulations into the US infant-immuni-
zation programme in 2000 has determined a significantly 
reduction in IPD incidence both in young children and in 
old age groups as a consequence of herd immunity [66]. 
However, a statistically significant rise in disease caused 
by non vaccine serotypes has been observed, in particu-
lar by serotypes 15B/15C/15F and 19A, but now also 
by serotypes 1, 3, 5, 6A, 7F. These serotypes and clones 
may be better adapted to colonize the nasopharynx, 
evade the human immune response, and cause disease. 
Further, a recent study showed an increase in prevalence 
of serotype 6C in children and a corresponding decrease 
in serotype 6A after introduction of PCV7 [67].
Serotypes included in the recently licensed 10-valent 
pneumococcal Haemophilus influenzae protein D con-
jugate vaccine (PCV10) and 13-valent pneumococcal 
conjugate vaccine (PCV13) account for pneumococcal 
disease burdens in most developed countries of 65–85% 
and 80–90%, respectively [68].
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The increasing diffusion of non vaccine serotypes may 
not necessarily reflect an increase in disease, infact, 
these serotypes are thought to have a relatively low 
disease potential. Nonetheless, the real potential of a 
serotype to cause disease also resides on the different 
exposures of children to each serotype. Therefore, se-
rotypes with low pathogenicity, but to which children 
are often exposed, may be more virulent than serotypes 
highly invasive but to which children are rarely ex-
posed to [40].
Moreover, the risk of vaccine-to-non vaccine sero-
type switch contributes to serotype replacement and 
may lead to vaccine escape events, which have the po-
tential to reduce vaccine effectiveness in the longer 
term [69].
Such considerations underline the importance of a con-
tinued epidemiological surveillance for the monitoring 
of changes in the incidence of IPD and non IPD, for de-
tecting genetic events such as transformation and recom-
bination, which may result in vaccine escape, and for 
determining eventual increase in non vaccine serotypes 
virulence. Furthermore, the importance of such a sur-
veillance resides on the consideration that the resulting 
knowledge of serotype-specific properties will represent 
a useful tool for the design and introduction of future 
pneumococcal vaccines into national programmes.
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